Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine

Study Status

Open to Enrollment

Study Description

In Myelodysplastic Syndrome (MDS), although the bone marrow can still make some blood cells, very few of these cells are released into the blood for use in the body. Therefore patients with Myelodysplastic Syndrome often need transfusions of red blood cells for anemia, platelet transfusions for low platelet counts or bleeding, and antibiotics for serious infections that can occur because of the low white blood cell counts. MDS can cause an accumulation of abnormal cells called blasts, putting patients at a high risk of developing leukemia.

The purpose of this study is to determine the efficacy and saftey of ON 01910.Na in treating Myelodysplastic Syndrome. ON 01910.Na is an experimental compound currently being tested in other clinical studies. 01919.Na has not been approved by the US Food and Drug Administration.

Disease Status and/or Stage

Myelodysplastic Syndromes (MDS) Including RAEB and Chronic Myelomonocytic Leukemia (CMML)


Onconova Therapeutics, Inc

Key Eligibility

  • Men and women age 18 and older
  • Diagnosis of Myelodysplastic Syndrome (MDS)
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Gail Roboz, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page